High Grade Glioma
Conditions
Keywords
Glioblastoma multiforme, FLT, PET
Brief summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
Interventions
DRUGFLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Each patient will have 0-3 or more FLT-PET brain scans.
Sponsors
Society of Nuclear Medicine and Molecular Imaging
General Electric
Marcelo F. Di Carli, MD, FACC
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT * Anticipated survival ≥6 months * Able to give informed consent * Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia * Male or Female
Exclusion criteria
* Prior radiation therapy and chemotherapy to the brain * Active intracranial infection or nonglial brain mass. * Recent large intracranial hemorrhage (\<1 month) * Expected survival \<6 months * Pregnant or nursing * Renal failure * Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 7 months | — |
| Progression free Survival | 7 months | MRI and clinical criteria |
Countries
United States
Outcome results
None listed